Last reviewed · How we verify
anti TNFa monoclonal antibody - Infliximab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
anti TNFa monoclonal antibody - Infliximab (anti TNFa monoclonal antibody - Infliximab) — KU Leuven.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| anti TNFa monoclonal antibody - Infliximab TARGET | anti TNFa monoclonal antibody - Infliximab | KU Leuven | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- anti TNFa monoclonal antibody - Infliximab CI watch — RSS
- anti TNFa monoclonal antibody - Infliximab CI watch — Atom
- anti TNFa monoclonal antibody - Infliximab CI watch — JSON
- anti TNFa monoclonal antibody - Infliximab alone — RSS
Cite this brief
Drug Landscape (2026). anti TNFa monoclonal antibody - Infliximab — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-tnfa-monoclonal-antibody-infliximab. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab